Literature DB >> 11772144

Immunisation safety: a priority of the World Health Organization's Department of Vaccines and Biologicals.

P Duclos1, C A Hofmann.   

Abstract

In 1999, the World Health Organization (WHO) Department of Vaccines and Biologicals launched the Immunisation Safety Priority Project to boost its activities in this area, with the aim of establishing a comprehensive system to ensure the safety of all immunisations given in national immunisation programmes. Countries are the primary focus of this project. The WHO has a role to play not only because of its technical and normative role but also because of its privileged relationship with country authorities and other partners, its global vision and mandate, and because it is perceived as free from conflicts of interest. There are four areas of focus in the project: quality control and assessment tools to ensure vaccine safety from clinical trials up to and including the point of use;research and development of safer and simpler delivery systems; access to safer and more efficient systems for vaccine delivery and sharps waste management; and mechanisms to respond promptly and effectively to vaccine safety concerns. The project emphasises the importance of advocating safety and developing necessary infrastructure and human resource to properly deal with immunisation related safety issues at a national level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11772144     DOI: 10.2165/00002018-200124150-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  14 in total

1.  Causality assessment of adverse events following immunization.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2001-03-23

2.  Developing a national system for dealing with adverse events following immunization.

Authors:  U Mehta; J B Milstien; P Duclos; P I Folb
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

3.  Oral poliovirus vaccine (OPV) and intussusception.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2000-10-27

4.  Adverse events monitoring as a routine component of vaccine clinical trials: evidence from the WHO Vaccine Trial Registry.

Authors:  M V Mayans; S E Robertson; P Duclos
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

5.  MEASLES IMMUNIZATION WITH KILLED VIRUS VACCINE. SERUM ANTIBODY TITERS AND EXPERIENCE WITH EXPOSURE TO MEASLES EPIDEMIC.

Authors:  L W RAUH; R SCHMIDT
Journal:  Am J Dis Child       Date:  1965-03

Review 6.  Unsafe injections in the developing world and transmission of bloodborne pathogens: a review.

Authors:  L Simonsen; A Kane; J Lloyd; M Zaffran; M Kane
Journal:  Bull World Health Organ       Date:  1999       Impact factor: 9.408

7.  Rates of first measles-mumps-rubella immunisation in Wales (UK)

Authors:  D R Thomas; R L Salmon; J King
Journal:  Lancet       Date:  1998-06-27       Impact factor: 79.321

8.  Impact of anti-vaccine movements on pertussis control: the untold story.

Authors:  E J Gangarosa; A M Galazka; C R Wolfe; L M Phillips; R E Gangarosa; E Miller; R T Chen
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

Review 9.  Simian virus 40, poliovirus vaccines, and human cancer: research progress versus media and public interests.

Authors:  J S Butel
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

10.  Examination of poliovirus vaccine preparations for SV40 sequences.

Authors:  D Sangar; P A Pipkin; D J Wood; P D Minor
Journal:  Biologicals       Date:  1999-03       Impact factor: 1.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.